Why the study?
Does LDL-C lowering therapy reduce cardiac events in diabetic patients?
Does LDL-C lowering therapy reduce cardiac events in diabetic patients?
Intensive lipid-lowering therapy, primarily with statins, is essential for reducing the high risk of cardiac events in diabetic patients.
Supports LDL-C lowering in diabetes to cut events; leaves open optimal targets and intensity in current practice.
Diabetes is considered to be a risk factor equivalent of pre-existing coronary heart disease for the development of future myocardial infarction and cardiovascular death. In addition toimproved glucose control, the increased risk of coronary disease in diabetics makes intensive lipid-lowering treatment necessary. A number of studies have demonstrated that lipid-lowering therapy in diabetes is effective in decreasing the number of cardiac events. The most important objective in the treatment of diabetes is to reduce LDL-C to a target of <100 mg/dl. Differenttypes of lipid-lowering drugs are available. Statins are the current lipid-lowering drugs ofchoice to reduce LDL-C.However, some questions remain unanswered. This article will describe and discuss the significance of LDL-C lowering therapy in subjects with diabetes.
No takes yet. Share an insight, caveat, or question.
Martinez-Hervas et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: